Design and Synthesis of a 2-Amino-pyridine Derivative as a Potent CDK8 Inhibitor for Anti-colorectal Cancer Therapy

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Cyclin-dependent kinase 8 (CDK8) is a potential therapeutic target in colon cancer.
• Developing selective CDK8 inhibitors is crucial for effective cancer treatment.

Purpose of the Study:

• To design, synthesize, and evaluate novel 2-amino-pyridine derivatives as selective CDK8 inhibitors.
• To assess the efficacy of a lead compound against colon cancer cell lines and *in vivo* models.

Main Methods:

• Structure-based drug design utilizing the sorafenib-bound CDK8 structure.
• Synthesis and *in vitro* evaluation of 2-amino-pyridine derivatives for CDK8 inhibition.
• Cell-based assays to determine antiproliferation, cell cycle arrest, and pathway modulation (WNT/β-catenin, TCF).
• Pharmacokinetic and *in vivo* antitumor efficacy studies.

Main Results:

• Compound 29 exhibited potent CDK8 inhibition (IC50 = 46 nM) with favorable selectivity.
• Compound 29 demonstrated antiproliferative effects on colon cancer cells, suppressed WNT/β-catenin signaling, and induced G1 arrest.
• The compound showed efficacy against sorafenib-resistant cells, indicating potential for overcoming drug resistance.
• Compound 29 displayed low toxicity and suitable pharmacokinetic properties, with significant *in vivo* antitumor activity.

Conclusions:

• Compound 29 is a potent and selective CDK8 inhibitor with significant therapeutic potential for colon cancer.
• This novel inhibitor effectively targets key cancer pathways and demonstrates efficacy in drug-resistant models.
• The favorable safety and pharmacokinetic profiles suggest compound 29 is a promising candidate for further clinical development.